PRESS RELEASES

This week we are celebrating the release of the 250th version of our drug discovery software platform! I am so incredibly proud of the improvements our software team is constantly pushing out; it is the foundation that supports twoXAR’s dedication to rapidly identifying treatments for patients in need.

Our platform makes drug discovery and development faster and with fewer false positives. To build this platform, we use an approach that tightly couples scientists and software developers to make R&D faster, more accurate, and/or cheaper...read post here.

I met Tim for the first time almost three years ago and I remember our meeting well. He furrowed his brow slightly as I explained the details on how our technology creates computational models of pathogenesis to derive new understanding of disease, and then identifies hits to test those new hypotheses within weeks instead of years. I’ve come to learn that the furrowed brow appears when the gears start turning in Tim’s head. And what exceptional gears they are... read post here.

Today I received an email from an influencer in the life science community. Paraphrasing a bit, here’s what she said:

“We have reviewed nearly 400 companies in this space — so much going on! How are you differentiated from others?”

Rather than email her individually, I viewed this as the perfect opportunity to share how twoXAR Pharmaceuticals is different. Our work is like nothing else... read post here.

As usual, there’s a lot of news coming out of the 38th Annual JPMorgan Chase Healthcare Conference. And machine learning’s ability to support the pharmaceutical research and development process is no exception. There have been dozens of presentations on this very topic, and even more companies pitching the promise of artificial intelligence (AI). But, one thing is very clear: More education is needed about how AI can support pharmaceutical research.... read post here.

Like many of you, I am winding down my work week to prepare for the holiday season. As a new decade approaches it is a good time to reflect on the events of the past year.

2019 saw tremendous growth for twoXAR. We launched nine new disease areas, expanding to new disease programs in our focus areas of ophthalmology, immunology & inflammatory, oncology and metabolic. We ended the year with eighteen total diseases in our portfolio, six of which have been out licensed...read post here.

Since co-founding twoXAR five years ago, I have consistently held the same beliefs about AI’s role in drug discovery, and I’ve delivered a consistent message about it. The world’s reaction to my words has evolved, from skepticism to curiosity to full-blown excitement.

Many believe AI is the panacea that will revolutionize the healthcare industry, and dollars are flowing into healthcare AI startups at unprecedented rates as investors make big bets on using the technology to analyze health data, improve efficiency in healthcare delivery, speed drug discovery, and offer new therapies for intractable diseases... read post here.